Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET

Company Participants

Danielle Jesse - Director, Investor Relations
Michael Heffernan - Interim President and Chief Executive Officer, Founder and Chairman
Scott Dreyer - Chief Commercial Officer
Colleen Tupper - Chief Financial Officer

Conference Call Participants

Les Sulewski - Truist Securities
David Amsellem - Piper Sandler
Serge Belanger - Needham & Company
Oren Livnat - H.C. Wainright

Operator

Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note that this conference call is being recorded.

I will now turn the call over to Danielle Jesse, Director of Investor Relations at Collegium. Please go ahead.

Danielle Jesse

Welcome to Collegium Pharmaceuticals third quarter 2024 earnings conference call. I am joined today by Mike Heffernan, our Interim President and Chief Executive Officer, Founder and Chairman; Colleen Tupper, our Chief Financial Officer; and Scott Dreyer, our Chief Commercial Officer.

Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional, and that any forward-looking statements made today are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. You are cautioned that such forward-looking statements involve risks and uncertainties including and without limitation, the risks that we may not be able to successfully commercialize our products, that we may incur significant expense in doing so, though we may not prevail in current or future litigation pertaining to our business. Risks related to our ability to realize the anticipated benefits and synergies of the recently completed acquisition of Ironshore. The risk that the businesses will not be integrated successfully and risks related to future opportunities and plans for Ironshore.

These risks and other risks of the company are detailed in the company's periodic reports filed with the Securities and Exchange Commission. Our future results may differ materially from our current expectations discussed today. Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations on our corporate website at collegiumpharma.com.

I will now turn the call over to our Chairman, Interim President and CEO, Mike Heffernan.

Michael Heffernan

Thank you, Danielle. Good afternoon, and thank you, everyone, for joining the call. Today, we will discuss Collegium's record financial performance during the third quarter and provide an update on our business, including the very exciting news that we have successfully completed our CEO search.